| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6091835 | Gastroenterology | 2016 | 50 Pages |
Abstract
Baseline RASs in NS5A have minimal effects on patient responses to ledipasvir/sofosbuvir therapy. When these RASs do have effects, they could be largely overcome by extending treatment duration or through treatment intensification.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Christoph Sarrazin, Hadas Dvory-Sobol, Evguenia S. Svarovskaia, Brian P. Doehle, Phillip S. Pang, Shu-Min Chuang, Julie Ma, Xiao Ding, Nezam H. Afdhal, Kris V. Kowdley, Edward J. Gane, Eric Lawitz, Diana M. Brainard, John G. McHutchison,